Síndrome de Down y enfermedad de Alzheimer: factores de riesgo, evaluación e intervención

  • Elvira Díaz Pérez Universidad de Oviedo
  • Laura E. Gómez Sánchez Universidad de Oviedo
  • Mª Ángeles Alcedo Rodríguez Universidad de Oviedo
Palabras clave: Síndrome de Down, Alzheimer, demencia, evaluación, tratamiento.

Resumen


Existe una estrecha relación entre el síndrome de Down y la enfermedad de Alzheimer. Diversos factores de riesgo influyen en esta relación, en la que la evaluación de la demencia es difícil debido a la falta de instrumentos y tratamientos específicos. Se realizó una búsqueda de los años comprendidos entre 2005-2015 en diferentes bases de datos. Se identificaron diversos factores de riesgo (genéticos, ambientales, cognitivos) y se encontraron varios instrumentos de evaluación, poco adecuados y/o con debilidades psicométricas. Los tratamientos existentes son escasos y, casi exclusivamente, farmacológicos. Se discute acerca de la importancia de llevar a cabo estudios sistemáticos sobre los factores de riesgo para la prevención de la enfermedad de Alzheimer en personas con síndrome de Down, así como la necesidad de un protocolo de evaluación específico y adaptado que permita implementar tratamientos más específicos y efectivos.

Biografía del autor/a

Elvira Díaz Pérez, Universidad de Oviedo

Graduada en Psicología y Máster en Psicología General Sanitaria por la Universidad de Oviedo. Es coautora del artículo “Stimuli with identical contextual functions taught independently become functionally equivalent”, publicado en Learning & Behavior en 2015. Ha trabajado como terapeuta de intervenciones asistidas con animales en Establecimientos Residenciales para Ancianos (ERA) de Asturias. Ha asistido a diferentes cursos y jornadas relacionadas con el ámbito de la discapacidad.

Laura E. Gómez Sánchez, Universidad de Oviedo

Doctora europea por la Universidad de Salamanca (2010), Premio Extraordinario de Doctorado y Premio Infanta Cristina 2010 en su modalidad de investigación. Actualmente es profesora ayudante doctora en el departamento de Psicología de la Universidad de Oviedo. Es coautora de siete instrumentos de evaluación de la calidad de vida para personas con discapacidad, (entre los que destacan GENCAT, INICO-FEAPS, San Martín, KidsLife) y numerosos artículos en revistas internacionales. Su línea preferente de investigación se centra en la calidad de vida de personas con discapacidad intelectual y otros colectivos en riesgo de exclusión social.

Mª Ángeles Alcedo Rodríguez, Universidad de Oviedo

Profesora titular del departamento de Psicología de la Universidad de Oviedo. Su actividad docente se centra en las materias de evaluación y diagnóstico psicológico, psicología de la discapacidad y violencia contra las mujeres. Es especialista en Psicología Clínica (MEC-Ministerio de Sanidad) y supervisora de programas de formación en el ámbito de la discapacidad.

En los últimos seis años ha realizado investigaciones y publicaciones en el ámbito de la psicología de la rehabilitación, psicología de la discapacidad, evaluación en rehabilitación, actitudes hacia las personas con discapacidad, discapacidad y envejecimiento, discapacidad y dependencia, discapacidad y universidad, y violencia de género en el ámbito de la discapacidad y de la exclusión social. En relación a estas temáticas ha participado en congresos nacionales e internacionales a través de comunicaciones y pósters. Es miembro del Instituto Universitario de Integración en la Comunidad de la Universidad de Salamanca (INICO) y de la Sociedad Asturiana de Psicología de la Rehabilitación (SAPRE).

Citas

Albert, M. y Cohen, C. (1992): “The test for severe impairment: An instrument for the assessment of patients with severe cognitive dysfunction”. Journal of the American Geriatics Society, 40: 449-453.

American Psychiatric Association (2013): Diagnostic and statistical manual of mental disorders (5ª ed.), Arlington, VA: American Psychiatric Association.

American Psychiatric Association (2000): DSM-IV-TR: Manual diagnóstico y estadístico de los trastornos mentales, Barcelona: Masson.

Avila, R. et al. (2007): “Neuropsychological rehabilitation in mild and moderate Alzheimer’s disease patients”. Behavioural Neurology, 18 (4): 225-233.

Bahar-Fuchs, A. et al. (2013): “Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia”. The Cochrane Database of Systematic Reviews, 5 (6): CD003260.

Ball, S.L. et al. (2006): “Personality and behavior changes mark the early stages of Alzheimer’s disease in adults with Down syndrome: Findings from a prospective population-based study”. International Journal of Geriatric Psychiatry, 21: 661-673.

Ball, S.L. et al. (2004): “The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down’s syndrome”. Journal of Intellectual Disability Research, 48: 611-620.

Benejam, B. et al. (2015): “Patterns of performance on the Modified Cued Recall Test in Spanish adults with Down syndrome with and without dementia”. American Journal on Intellectual and Developmental Disabilities, 120 (6): 481- 489.

Benejam, B. (2009): “Síntomas de demencia en el síndrome de Down”. Revista Médica Internacional sobre el síndrome de Down, 13 (2): 18-21.

Bittles, A.H. y Glasson, E.J. (2004): “Clinical, social and ethical implications of changing life expectancy in Down syndrome”. Developmental Medicine and Child Neurology, 46: 282-286.

Boada-Rovira, M. et al. (2005): “Estudio clinicoterapéutico de la demencia en las personas con síndrome de Down y eficacia del donepecilo en esta población”. Revista de Neurología, 41 (3): 129-136.

Borrel, J.M. (2012): “Cuidados de salud en el adulto con síndrome de Down”. Revista Española de Pediatría Clínica e Investigación, 68 (6): 448-485.

Burt, D.B. y Aylward, E.H. (2000): “Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability”. Journal of Intellectual Disability Research, 44: 175-180.

Burt, D.B. y Aylward, E.H. (1998): Test battery for the diagnosis of dementia in individuals with intellectual disability, Washington, D.C.: American Association of Mental Retardation.

Burt, D.B. et al. (2005): “Comparing dementia diagnostic methods used with people with intellectual disabilities”. Journal of Policy and Practice in Intellectual Disabilities, 2: 94-115.

Bush, A. y Beail, N. (2004): “Risk factors for dementia in people with Down syndrome: issues in assessment and diagnosis”. American Journal on Mental Retardation, 109: 83-97.

Catuara-Solarz, S. et al. (2015): “Principal component analysis of the effects of environmental enrichment and (-)-epigallocatechin-3-gallate on age-associated learning deficits in a mouse model of Down syndrome”. Frontiers in Behavioral Neuroscience, 9 (330): 1-14.

Clare, L. (2011): “Intervención de la memoria en el envejecimiento y las demencias”, en Bruna, O. et al. (eds.): Rehabilitación Neuropsicológica: intervención y práctica clínica. Barcelona: Elsevier Masson.

Clare, L. (2008): Neuropsychological rehabilitation and people with dementia, New York: Psychology Press.

Clare, L. et al. (2003): “Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s disease and vascular dementia”. The Cochrane Library, 4.

Colcombe, S. y Kramer, A.F. (2003): “Fitness effects on the cognitive function of older adults: a meta-analytic study”. Psychological Science, 14 (2): 125-130.

Cooper, S.A. et al. (2014): “Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial”. Trials, 15 (202): 1-14.

Coppus, A. et al. (2006): “Dementia and mortality in person with Down’s syndrome”. Journal of Intellectual Disability Research, 50 (10): 768- 777.

Cramer, P.E. et al. (2012): “ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models”. Science, 335 (6075): 1503-1506.

Dalton, A. y Fedor, B. (1998): “Onset of dyspraxia in aging persons with Down syndrome: Longitudinal studies”. Journal of Intellectual and Developmental Disability, 23 (1): 13-24.

De Deyn et al. (2005): “Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials ins nursing home residents treated with risperidone”. Clinical Neurology and Neurosurgery, 107 (6): 497-508.

De la Torre, R. et al. (2013): “Epigallocatechin-3- gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans”. Molecular Nutrition and Food Research, 58 (2): 278-288.

De Vreese, L.P. et al. (2012): “Impact of dementia-derived nonpharmacological intervention procedures on cognition and behavior in older adults with intellectual disabilities: a 3-year follow-up study”. Journal of Policy and Practice in Intellectual Disabilities, 9 (2): 92-102.

Deb, S. et al. (2007): “The dementia screening questionnaire for individuals with intellectual disabilities”. British Journal of Psychiatry, 190: 440-444.

Dekker, A.D. et al. (2015): “Behavioural and psychological symptons of dementia in Down syndrome: Early indicators of clinical Alzheimer’s disease?” Cortex, 73: 36-61.

Down España (2012): Down España en la ONU con motivo del Día Mundial del Síndrome de Down (en línea). <http://www.sindromedown. net/noticia/down-espana-en-la-onu-con-motivo-del-dia-mundial-del-sindrome-de-down/>, acceso 13 de junio de 2016.

Esbensen, A.J. et al. (2013): “Long-term impact of parental well-being on adult outcomes and dementia status in individuals with Down syndrome”. American Journal of Intellectual and Developmental Disabilities, 118 (4): 294- 309.

Esteba-Castillo, S. et al. (2013): “Adaptación y validación del Cambridge Examination for Mental Disorders of Older People with Down’s Syndrome and Others with Intellectual Disabilities (CAMDEX-DS) en población española con discapacidad intellectual”. Revista de Neurología, 57 (8): 337-346.

Evenhuis, H.M. et al. (2007): Dementia Questionnaire for people with learning disabilities (DLD), Uk adaptation, San Antonio, TX: Harcourt Assessment.

Evenhuis, H.M. et al. (2000): Healthy ageing- Adults with Intellectual Disabilities: Physical Health Issues, Ginebra: World Health Organization.

Evenhuis, H.M. et al. (1990): Dementia Questionnaire for Mentally Retarded Persons, Zwammerdam: Hooge Burch.

Farriols, C. (2012): “Aspectos específicos del envejecimiento en el síndrome de Down”. Revista Médica Internacional sobre el Síndrome de Down, 16 (1): 3-10.

Felstrom, A. et al. (2005): “Refining diagnoses: applying the DC-LD to an Irish population with intellectual disability”. Journal of Intellectual Disability Research, 49 (11): 813- 819.

Fernández-Ríos, L. y Buela-Casal, G. (2009): “Standards for the preparation and writing of Psychology review articles”. International Journal of Clinical and Health Psychology, 9 (2): 329-344.

Finlay, W.M. y Lyons, E. (2001): “Methodological issues in interviewing and using self-report questionnaires with people with mental retardation”. Psychological Assessment, 13: 319-335.

Fischer, A. (2016): Environmental enrichment as a method to improve cognitive function. What can we learn from animal models? (en línea). <http://www.sciencedirect.com/science/article/ pii/S1053811915010617>, acceso 15 de junio de 2016.

Flórez, J. (2010): “Enfermedad de Alzheimer y síndrome de Down”. Revista síndrome de Down, 27: 63-76.

Flórez, J. et al. (2015): “El envejecimiento en las personas con síndrome de Down”, en Flórez, J. et al. (coords.): Síndrome de Down: Neurobiología, Neuropsicología, Salud mental. Madrid: Editorial Cepe.

Garvía, B. (2014): Trastornos mentales en el síndrome de Down (en línea). < http://www. sindromedownvidaadulta.org/revista-de-adultos-n-17-junio-2014/articulos-no17/ trastornos-mentales-en-el-sindrome-de-down/>, acceso 15 de junio de 2016.

Gedye, A. (1995): Dementia Scale for Down Syndrome, Vancouver, BC: Gedye Research and Consulting.

Ghezzo, A. et al. (2014): “Age-related changes of adaptive and neuropsychological features in persons with Down syndrome”. Plos One, 9 (11): 1-21.

Glasson, E.J. et al. (2014): “The triple challenges associated with age-relates comorbidities in Down syndrome”. Journal of Intellectual Disability Research, 58: 393-398.

Hanney, M. et al. (2012): “Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomized, double-blind, placebo-controlled trial”. The Lancet, 379 (9815): 528-536.

Hanney, M.L. et al. (2009): “Overview of the Neuropshychological assessment of dementia and intellectual disability”, en Prasher, V.P. (ed.): Neuropsychological assessments of dementia in Down syndrome and intellectual disabilities. Londres: Springer-Verlag.

Hartley, D. et al. (2015): “Down syndrome and Alzheimer’s disease: Common pathways, common goals”. Alzheimer and Dementia, 11: 700-709.

Haxby, J.V. (1989): “Neuropsychological evaluation of adults with Down syndrome: Patterns of selective impairment in adults non-demented old adults”. Journal of Mental Deficiency Research, 33: 193-210.

Hayn, M. et al. (1996): “Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down’s syndrome and Alzheimer’s disease”. Life Science, 59: 537-544.

He, G. et al. (2010): “Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease”. Nature, 467 (7311): 95-98.

Head, E. et al. (2012): “Aging and Down syndrome”. Current gerontology and Geriatrics Research, 2012: 1-6.

Hermans, H. y Evenhuis, H.M. (2014): “Multimorbidity in older adults with intellectual disabilities”. Research in Developmental Disabilities, 35: 776-783.

Holland, A.J. (1995): “Down’s syndrome and the links with Alzheimer’s disease”. Journal of Neurology Neurosurgery and Psychiatry, 59: 111-114.

Holland, A.J. y Ball, S.L. (2009): “The Cambridge Examination for Mental Disorders of older people with Down Syndrome and Others with Intellectual Disabilities (CAMDEX-DS)”, en Prasher, V.P. (ed.): Neuropsychological assessments of dementia in Down syndrome and intellectual disabilities. Londres: Springer- Verlag.

Hoshino, T. et al. (2002): “Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer’s disease”. Neurobiology of aging, 23 (1): 41-45.

Isbir, T. et al. (2001): “Apolipoprotein-E gene polymorphism and lipid profiles in Alzheimer’s disease”. American Jounal of Alzheimer’s Disease and other Dementias, 16 (2): 77-81.

Isobe, Y. et al. (2009): “Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate”. Internal Medicine Journal, 39 (6): 408-411.

Jankowsky, J.L. et al. (2005): “Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer’s disease”. Journal of Neuroscience, 25: 5217-5224.

Jones, E.L. et al. (2013): “Evidence that PICALM affects age at onset of Alzheimer’s dementia in Down syndrome”. Neurobiology of Aging, 34 (10): 2441.e1-2441e5.

Jozsvai, E. et al. (2009): “Dementia Scale for Down Syndrome”, en Prasher, V.P. (ed.): Neuropsychological assessments of dementia in Down syndrome and intellectual disabilities. Londres: Springer-Verlag.

Kalsy-Lillico, S. (2014): “Living life with dementia: Enhancing Psychological wellbeing”, en Watchman, K. (ed.): Intellectual Disability and Dementia: Research into Practice. Londres: Jessica Kingsley Publishers.

Kalsy-Lillico, S. et al. (2012): “Older adults with intellectual disability: Issues in ageing and dementia”, en Emerson, E. et al. (eds.): Clinical Psychology and People with Intellectual Disabilities. Chichester: Wiley.

Key, A.P. y Dykens, E.M. (2014): “Event-related potential index of age-related differences in memory processes in adults with Down syndrome”. Neurobiology of Aging, 35 (1): 247-253.

Krinsky-McHale, S.J. et al. (2008): “Selective attention deficits associated with mild cognitive impairment and early stage Alzheimer’s disease in adults with Down syndrome”. American Journal on Mental Retardation, 113: 369-386.

Landau, S.M. et al. (2012): “Association of lifetime cognitive engagement and low ß-amyloid deposition”. Archives of Neurology, 69 (5): 623-629.

Launer, L.J. et al. (2001): “Cholesterol and neuropathologic markers of AD: a population-based autopsy study”. Neurology, 57 (8): 1447-1452.

Lesko, L.J. y Atkinson, A.J. (2001): “Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies”. Annual Review of Pharmacology and Toxicology, 41: 347-366.

Loane, M. et al. (2013): “Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening”. European Journal of Human Genetics, 21: 27-33.

López-Locanto, O. (2015): “Tratamiento farmacológico de la enfermedad de Alzheimer y otras demencias”. Archivos de Medicina Interna, 37 (1): 61-67.

Lott, I.T. y Head, E. (2001): “Down syndrome and Alzheimer’s disease: a link between development and aging”. Mental Retardation and Developmental Disabilities Research Reviews, 7: 172-178.

Malea-Fernández, I. et al. (2014): “Neurología y Síndrome de Down. Desarrollo y atención temprana”. Revista Española de Pediatría, 68 (6): 409-414.

Mascarenhas-Fonseca, L. et al. (2015): “Cognitive rehabilitation of dementia in adults with Down syndrome: a review of non-pharmacological interventions”. Dementia and Geriatric Cognitive Disorders, 5: 330-340.

Mausner, J.S. y Kramer, S. (1985): Mausner and Bahn epidemiology: an introductory text, Philadelphia, PA: W.B. Saunders.

Mawuenyega, K.G. et al. (2010): “Decreased clearance of CNS beta-amyloid in Alzheimer’s disease”. Science, 330 (6012): 1774-1776.

McCarron, M. et al. (2005): “Health co-morbidities in ageing persons with Down syndrome and Alzheimer’s dementia”. Journal of Intellectual Disability Research, 49 (7): 560- 566.

McGuire, B.E. et al. (2006): “Alzheimer’s disease in Down syndrome and intellectual disability: A review”. Irish Journal of Psychology, 27 (3-4): 114-129.

Moceri, V.M. et al. (2001): “Using census data and birth certificates to reconstruct the early-life socioeconomic environment and the relation to the development of Alzheimer’s disease”. Epidemiology, 12: 383-389.

Mohan, M. et al. (2009a): “Galantamine for dementia in people with Down syndrome”. The Cochrane Database of Systematic Reviews, 21 (1): CD007656.

Mohan, M. et al. (2009b): “Rivastigmine for dementia in people with Down syndrome”. The Cochrane Database of Systematic Reviews, 21 (1): CD007658.

Moran, J.A. et al. (2013): “The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities”. Mayo Clinic Proceedings, 88 (8): 831-840.

Muchova, J. et al. (2014): “Oxidative stress and Down syndrome. Do antioxidants play a role in therapy?”. Physiological Research, 63: 535- 542.

Mullins, D. et al. (2013): “Dementia in Down’s syndrome: an MRI comparison with Alzheimer’s disease in the general population”. Journal of Neurodevelopmental Disorders, 5 (19): 1-13.

Mulryan, N.M. et al. (2009): “The test for Severe Impairment”, en Prasher, V.P. (ed.): Neuropsychological assessments of dementia in Down syndrome and intellectual disabilities. Londres: Springer-Verlag.

Nakamura, E. y Tanaka, S. (1998): “Biological ages of adult men and women with Down’s syndrome and its changes with aging”. Mechanisms of Ageing and Development, 105: 89-103.

Neal, M. y Barton-Wright, P. (2003): “Validation therapy for dementia”. The Cochrane Database of Systematic Reviews, 3: CD001394.

Neal, M. y Briggs, M. (2000): “Validation therapy for dementia”. The Cochrane Database of Systematic Reviews, 2: CD001394.

Nieuwenhuis-Mark, R.E. (2009): “Diagnosing Alzheimer’s dementia in Down syndrome: Problems and possible solutions”. Research in Developmental Disabilities, 30: 827-838.

O’Caoimh, R. et al. (2013): “Screening for Alzheimer’s Disease in Down’s syndrome”. Journal of Alzheimer’s Disease and Parkinsonism, S7 (001): 1-6.

Organización Mundial de la Salud (1992): The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research, Ginebra: World Health Organization.

Parajua-Pozo, J.L. y Casis-Arguea, S. (2000): “Síndrome de Down y demencia”. Revista de Neurología, 31 (2): 126-128.

Phillips, C. et al. (2015): “The link between physical activity and cognitive dysfunction in Alzheimer disease”. Physical Therapy, 95 (7): 1046-1060.

Prasher, V.P. (2009): “The Adaptative Behavior Dementia Questionnaire (ABDQ)”, en Prasher, V.P. (ed.): Neuropsychological assessments of dementia in Down syndrome and intellectual disabilities. Londres: Springer-Verlag.

Prasher V.P. et al. (2004): “The adaptive Behaviour Dementia Questionnaire (ABDQ): Screening Questionnaire for dementia of Alzheimer’s disease in adults with Down syndrome”. Research in Developmental Disabilities, 25: 385-397.

Prasher, V.P. et al. (2003): “Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer’s disease in adults with Down syndrome: open label study”. International Journal of Geriatric Psychiatry, 18 (6): 549-551.

Presson, A.P. et al. (2013): “Current estimate of Down syndrome population prevalence in the United States”. The journal of Pediatrics, 163 (4): 1163-1168.

Rabinowitz, J. et al. (2007): “Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer’s disease using risperidone”. International Psychogeriatrics/ IPA, 19 (2): 227-240.

Ringman, J.M. et al. (2014): “Genetic heterogeneity in Alzheimer disease and implications for treatment strategies”. Current Neurology and Neuroscience Reports, 14 (499): 1-9.

Ringman, J.M. et al. (2012): “Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype”. Archives of Neurology, 69 (6): 757-764.

Royal College of Psychiatrists (2001): DC-LD (Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities/ Mental Retardation), Londres: Gaskell Press.

Saxton, J. et al. (1990): “Assessment of the severely impaired patient: Description and validation of a new neuropsychological test battery psychological assessment”. Journal of Consulting and Clinical Psychology, 2: 298- 303.

Schupf, N. et al. (2006): “Bioavailable estradiol and age at onset of Alzheimer’s disease in postmenopausal women with Down syndrome”. Neuroscience Letters, 406: 298- 302.

Schupf, N. et al. (2003): “Onset of dementia is associated with age at menopause in women with Down’s syndrome”. Annals of Neurology, 54: 433-438.

Schupf, N. et al. (1998): “Earlier onset of Alzheimer’s disease in men with Down syndrome”. Neurology, 50: 991-995.

Sekijima, Y. et al. (1998): “Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down’s syndrome”. European Neurology, 39 (4): 234- 237.

Small, J.A. (2012): “A new frontier in spaced retrieval memory training for persons with Alzheimer’s disease”. Neuropsychological Rehabilitation, 22 (3): 329-361.

Smith, D.S. (2001): “Health care management of adults with Down syndrome”. American Family Physician, 64: 1031-1038.

Smith, P.J. et al. (2010): “Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials”. Psychomatic Medicine, 72 (3): 239-252.

Spector, A. et al. (2000): “Reality orientation for dementia”. The Cochrane Database of Systematic Reviews, 4: CD001119.

Stancliffe, R. et al. (2012): “Demographic Characteristics, Health Conditions, and Residential Service Use in Adults with Down Syndrome in 25 US States”. Intellectual and Developmental Disabilities, 50 (2): 92-108.

Strydom, A. y Hassiotis, A. (2003): “Diagnostic instruments for dementia in older people with intellectual disability in clinical practice”. Aging and Mental Health, 6: 431-437.

Strydom, A.et al. (2013a): “Incidence of dementia in older adults with intellectual disabilities”. Research in Developmental Disabilities, 34: 1881-1885.

Strydom, A. et al. (2013b): “Validity of criteria for dementia in older people with intellectual disability”. The American Journal of Geriatric Psychiatry, 21 (3): 279-288.

Strydom, A. et al. (2010): “Dementia in older adults with intellectual disabilities – Epidemiology, presentation, and diagnosis”. Journal of Policy and Practice in Intellectual Disabilities, 7: 96-110.

Strydom, A. et al. (2007): “Prevalence of dementia in intellectual disability using different diagnostic criteria”. The British Journal of Psychiatry, 191: 150-157.

Subirana-Mirete, J. et al. (2011): “Demencias y enfermedad de Alzheimer”, en Bruna, O. et al. (eds.): Rehabilitación neuropsicológica: intervención y práctica clínica. Barcelona: Masson.

Temple, V. et al. (2001): “Alzheimer’s dementia in Down’s syndrome: the relevance of cognitive ability”. Journal of Intellectual Disability Research, 45: 47-55.

Tsao, R. et al. (2015): “Variability of the Aging Process in Dementia-Free Adults with Down syndrome”. American Journal of Intellectual and developmental disabilities, 120 (1): 3-15.

Tyrrell, J. et al. (2001): “Dementia in people with Down’s syndrome”. International Journal of Geriatric Psychiatry, 16: 1168-1174.

Tyrrell, J. et al. (1996): “Dementia in an Irish population of Down syndrome people”. Irish Journal of Psychological Medicine, 13 (2): 51-54.

Van der Flier, W.M. (2005): “Epidemiology and risk factors of dementia”. Journal of Neurology, Neurosurgery and Psychiatry, 76 (5): 2-7.

Weksler, M.E. et al. (2013): “Alzheimer’s disease and Down’s syndrome: treating two paths to dementia”. Autoinmunity Reviews, 12: 670- 673.

Woods, R.T. (2002): “Reality orientation: a welcome return?” Age and ageing, 31 (3): 155- 156.

Woods, R.T. (1999): “Psychological therapies in dementia”, en Woods, R.T. (ed.): Psychological problems of aging: assessment, treatment and care. Chichester: John Wiley and sons Ltd.

Woods, B. et al. (2005): “Reminiscence therapy for dementia”. The Cochrane Database of Systematic Reviews,18 (2): CD001120.

Zeilinger, E.L. et al. (2013a): “CAPs-IDD: Characteristics of assessment instruments for psychiatric disorders in persons with intellectual developmental disorders”. Journal of Intellectual Disability Research, 57 (8): 737- 746.

Zeilinger, E.L. et al. (2013b): “A systematic review on assessment instruments for dementia in persons with intellectual disabilities”. Research in developmental disabilities, 34 (11): 3962- 3977.

Zigman, W.B. y Lott, I.T. (2007): “Alzheimer’s disease in Down syndrome: Neurobiology and risk”. Mental Retardation and Developmental Disabilities Research Reviews, 13: 237-246.

Publicado
2016-06-29